Catalysts for Genentech Inc

ITOVEBI (INAVOLISIB) — FDA approval

VABYSMO (FARICIMAB-SVOA) — FDA approval

KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval

POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

LUNSUMIO (MOSUNETUZUMAB-AXGB) — FDA approval

GAZYVA (OBINUTUZUMAB) — FDA approval

ACTEMRA (TOCILIZUMAB) — FDA approval

ACTEMRA (TOCILIZUMAB) — FDA approval

TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approval

TECENTRIQ (ATEZOLIZUMAB) — FDA approval

TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approval

COLUMVI (GLOFITAMAB-GXBM) — FDA approval

GAZYVA (OBINUTUZUMAB) — FDA approval

GAZYVA (OBINUTUZUMAB) — FDA approval

TECENTRIQ (ATEZOLIZUMAB) — FDA approval

TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approval

ITOVEBI (INAVOLISIB) — FDA approval

TECENTRIQ (ATEZOLIZUMAB) — FDA approval

TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approval

ACTEMRA (TOCILIZUMAB) — FDA approval

ACTEMRA (TOCILIZUMAB) — FDA approval

COLUMVI (GLOFITAMAB-GXBM) — FDA approval

KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval